2024-05-30Zeitschriftenartikel
Long-acting prescriptions and therapy for HIV-1 from market launch to the present in Germany (May 2021 to December 2023)
Schmidt, Daniel; Kollan, Christian; Stoll, Matthias
Background:
In Europe, the combination of cabotegravir (CAB) with rilpivirine (RPV) has been approved as a dual injection long-acting (LA) therapy for the treatment of human immunodeficiency virus type 1 (HIV-1) infections ...
